司美格鲁肽与利拉鲁肽治疗糖尿病合并肥胖症的效果对比

Comparison of the Effects of Semaglutide and Liraglutide in the Treatment of Diabetes Mellitus Complicated with Obesity

目的:探究司美格鲁肽与利拉鲁肽在治疗糖尿病合并肥胖症患者中的临床价值。方法:选择2021年8月—2023年4月于本院接受治疗的100例糖尿病合并肥胖症患者为研究对象,按照随机数字表法分为观察组和对照组,每组50例。对照组予以利拉鲁肽治疗,观察组予以司美格鲁肽治疗,比较两组糖代谢指标水平、血脂代谢指标水平、氧化应激指标水平、不良反应。结果:治疗12周后,观察组FBG水平、HOMA-IR、低密度脂蛋白水平、总胆固醇水平、BMI指数以及腹围均低于对照组,高密度脂蛋白水平高于对照组(P<0.05);观察组不良反应总发生率与对照组比较,差异无统计学意义(P>0.05)。结论:司美格鲁肽与利拉鲁肽在改善糖尿病合并肥胖症血糖、血脂及体重指标方面均具有较好的效果,安全性也相当,但司美格鲁肽较利拉鲁肽效果更好。

Objective:To explore the clinical value of simegallutide and liraglutide in the treatment of diabetes mellitus complicated with obesity.Methods:A total of 100 patients with diabetes mellitus complicated with obesity who were treated in our hospital from August 2021 to April 2023 were selected as the research objects.According to the random number table method,they were divided into observation group and control group,with 50 patients in each group.The control group was treated with liraglutide,and the observation group was treated with semeglutide.The levels of glucose metabolism indexes,blood lipid metabolism indexes,oxidative stress indexes and adverse reactions were compared between the two groups.Results:After 12 weeks of treatment,the FBG level,HOMA-IR,low density lipoprotein level,total cholesterol level,BMI index and abdominal circumference of the observation group were lower than those of the control group,and the high density lipoprotein level was higher than that of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion:Simegallutide and liraglutide had good effect in improving blood glucose,lipid and body weight indexes in diabetes and obesity,and comparable safety,but simegallutide had better effect than that in liraglutide.